Francisco Javier Olascoaga Urtaza

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

Spanish Registry of patients with Multiple Sclerosis (MS) treated with fingolimod (GILENYA Registry): safety and effectiveness after four years. Patients without previous treatment subanalysis (P6.395)

X. Montalban, J. Álvarez-cermeño, C. Oreja-Guevara, 2018 .